Prosthetic valve thrombosis (PVT) is a severe and life-threatening complication of heart valve replacement. Conventional therapy is surgical thrombectomy or valve replacement. Medical thrombolysis is another emerging option. We report the case of a 57 year old woman with a history of Ebstein anomaly who underwent successful treatment of tricuspid prosthetic valve thrombosis with intra-atrial infusion of very low dose recombinant tissue plasminogen activator (tPA). We review the presentation, etiology, diagnosis, and treatment of tricuspid PVT emphasizing a modified medical option as a safe, minimally invasive alternative to surgical intervention or conventional medical therapy for tricuspid valve thrombosis.
- Ebstein anomaly
- Prosthetic valve
- Recombinant tissue plasminogen activator (tPa)
- Thrombosis, thrombolysis, fibrinolysis
- Tricuspid valve
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine